(Q24201588)

6

0 references

7

Brian R Davidson

Brian R

Davidson

1 reference

19 October 2023

Andrew Kenneth Burroughs

8

Andrew K Burroughs

Andrew K

Burroughs

1 reference

19 October 2023

Kurinchi Selvan Gurusamy

6

object named as

Kurinchi Selvan Gurusamy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599819&resulttype=core&format=json

15 May 2020

1

Ronald L Koretz

Ronald L

Koretz

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599819&resulttype=core&format=json

15 May 2020

19 October 2023

Maria Pleguezuelo

2

Maria

Pleguezuelo

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599819&resulttype=core&format=json

15 May 2020

19 October 2023

Vasiliki Arvaniti

3

author given names

Vasiliki

author last names

Arvaniti

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599819&resulttype=core&format=json

15 May 2020

19 October 2023

Pilar Barrera Baena

4

author given names

Pilar

author last names

Barrera Baena

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599819&resulttype=core&format=json

15 May 2020

19 October 2023

Ruben Ciria

5

author given names

Ruben

author last names

Ciria

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599819&resulttype=core&format=json

15 May 2020

Cochrane Database of Systematic Reviews

19 October 2023

language of work or name

1 reference

31 January 2013

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599819&resulttype=core&format=json

15 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599819&resulttype=core&format=json

15 May 2020

page(s)

CD003617

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599819&resulttype=core&format=json

Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial

15 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

The sustained virologic response of nonresponder hepatitis C virus patients with retreatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Therapy of hepatitis C: re-treatment with alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Interferon retreatment of nonresponders with HCV-RNA-positive chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Triple antiviral therapy in HCV positive patients who failed prior combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Dose increase augments response rate to interferon-alpha in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Human leucocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Re-treatment of chronic hepatitis C with consensus interferon .

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Retreatment with interferon in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

A randomized controlled trial of interferon-alpha in patients with cirrhosis caused by 2a/2b genotype hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Retreatment with interferon-alpha of chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

r-Interferon alfa-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Effectiveness of leukocyte interferon-alpha treatment in patients with chronic hepatitis C not responsive to recombinant interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Pilot study of interferon gamma for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Prediction of treatment outcome with daily high-dose IFN alpha-2b plus ribavirin in patients with chronic hepatitis C with genotype 1b and high HCV RNA levels: relationship of baseline viral levels and viral dynamics during and after therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Interferon Alpha Therapy in Patients with Chronic Type C Hepatitis: Changes of serum ALT, Anti-HCV & HCV-RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Ribavirin monotherapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Ribavirin plus interferon versus interferon for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Intention-to-treat analysis: implications for quantitative and qualitative research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

45-year follow-up of hepatitis C virus infection in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617.PUB2

Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.

21 January 2018

1 reference

12 December 2020

Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone.

1 reference

12 December 2020

The retreatment with natural leukocyte interferon alfa-n3 of chronic hepatitis C patients: the intolerant and nonresponsive results to prior treatment with recombinant alfa interferon

1 reference

12 December 2020

Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group

1 reference

12 December 2020

Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial

1 reference

12 December 2020

Biochemical and virological changes in serum of nonresponder or relapser chronic hepatitis C patients retreated with interferon and ribavirin followed by interferon alone

1 reference

12 December 2020

Retreatment with interferon for chronic hepatitis C after transient response

1 reference

12 December 2020

Interferon-alpha plus ribavirin combination therapy for the treatment of chronic hepatitis C in interferon non-responders.

1 reference

12 December 2020

Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

1 reference

12 December 2020

Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon

1 reference

12 December 2020

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

12 December 2020

[Induction therapy with interferon alfa-2a in compensated hepatitis C virus-related cirrhosis. Randomized, multicenter study]

1 reference

12 December 2020

[Hepatocarcinoma in HCV compensated correlated liver cirrhosis: role of treatment with interferon]

1 reference

12 December 2020

Course and outcome of hepatitis C

1 reference

12 December 2020

Treatment of patients with hepatitis C and cirrhosis

1 reference

12 December 2020

A randomized clinical trial with natural interferon-alpha monotherapy for 24 or 48 weeks on patients with chronic hepatitis C having genotype 1b infection in high viral titers

1 reference

12 December 2020

Retreatment of chronic hepatitis C with interferon-alpha

1 reference

12 December 2020

Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C.

1 reference

12 December 2020

Efficacy of early retreatment with interferon beta for relapse in patients with genotype Ib chronic hepatitis C

1 reference

12 December 2020

Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis.

1 reference

12 December 2020

Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin

1 reference

12 December 2020

Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.

1 reference

12 December 2020

Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders

1 reference

12 December 2020

Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals

1 reference

12 December 2020

Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: the plot thickens

1 reference

12 December 2020

Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis: A meta-analysis of randomized controlled trials

1 reference

12 December 2020

Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-alpha

1 reference

12 December 2020

Interferon-alpha retreatment in chronic hepatitis C

1 reference

12 December 2020

A preliminary study of retreatment of chronic hepatitis C with interferon

1 reference

12 December 2020

Retreatment with interferon in patients with chronic hepatitis C

1 reference

12 December 2020

Retreatment of chronic hepatitis C virus infection

1 reference

12 December 2020

Long-term response to interferon-alfa 2b re-treatment in chronic hepatitis C

1 reference

12 December 2020

Interferon and hepatocellular carcinoma

1 reference

12 December 2020

High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial

1 reference

12 December 2020

Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.

1 reference

12 December 2020

Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group

1 reference

12 December 2020

Long-term interferon alfa-2b retreatment of relapsing patients with chronic hepatitis C

1 reference

12 December 2020

Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone

1 reference

12 December 2020

Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study

1 reference

12 December 2020

Management of hepatitis C

1 reference

12 December 2020

Value of high-dose interferon-alpha in chronic viral hepatitis C patients non-responder to a 1st treatment. Pilot study prospective and randomized trial

1 reference

12 December 2020

Retreatment with human leukocyte interferon alpha of chronic hepatitis C, recurring after a first cycle with recombinant interferon.

1 reference

12 December 2020

Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study

1 reference

12 December 2020

10.1002/14651858.CD003617.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599819&resulttype=core&format=json

release_tflzdh2sore7lgujlkfpicft4m

15 May 2020

Fatcat ID

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599819&resulttype=core&format=json

15 May 2020

1 reference